Literature DB >> 25294531

Should prophylactic cholecystectomy be performed in patients with concomitant gallstones after endoscopic sphincterotomy for bile duct stones?

Jun Heo1, Min Kyu Jung, Chang Min Cho.   

Abstract

BACKGROUND: Endoscopic sphincterotomy (EST) is the standard treatment for biliary duct stones. However, performing additional cholecystectomy after EST is controversial. In this study, we aimed to evaluate the effects of cholecystectomy after EST.
METHODS: Between December 2008 and July 2011, we performed a prospective, randomized, single-center trial in 90 patients with proven gallstones who underwent EST and stone extraction. After the procedure, patients were randomly allocated to undergo cholecystectomy (n = 45) or to the group of GB left in situ (n = 45). The primary outcome was biliary complications at follow-up.
RESULTS: Cholecystectomy was performed in 26 patients (60.5 %) in cholecystectomy group and in 13 patients (28.9 %) in intended conservative group. The median follow-up was 41 months. An intention-to-treat analysis showed that 8 patients (18.6 %) in the cholecystectomy group and 9 (20.0 %) in those who had their GB left in situ had recurrent biliary events (Kaplan-Meier curve, Breslow test, p = 0.555). In an as-treated analysis, 4 patients (10.3 %) who underwent cholecystectomy and 13 patients (26.5 %) who did not undergo cholecystectomy had additional biliary events during the follow-up period (Log-rank, p = 0.037). However, additional biliary events of cholangitis were similar in the two groups, except for a case of cholecystitis (Log-rank, p = 0.998).
CONCLUSIONS: Cholecystectomy after EST for biliary duct stones fails to reduce additional recurrent cholangitis but reduces additional cholecystitis.

Entities:  

Mesh:

Year:  2014        PMID: 25294531     DOI: 10.1007/s00464-014-3844-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  17 in total

1.  Reasons for conversion from laparoscopic to open cholecystectomy: a 10-year review.

Authors:  Juliane Bingener-Casey; Melanie L Richards; William E Strodel; Wayne H Schwesinger; Kenneth R Sirinek
Journal:  J Gastrointest Surg       Date:  2002 Nov-Dec       Impact factor: 3.452

2.  Composition of common bile duct stones in Chinese patients during and after endoscopic sphincterotomy.

Authors:  Wei-Lun Tsai; Kwok-Hung Lai; Chiun-Ku Lin; Hoi-Hung Chan; Ching-Chu Lo; Ping-I Hsu; Wen-Chi Chen; Jin-Shiung Cheng; Gin-Ho Lo
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

3.  Outcomes analysis of laparoscopic cholecystectomy in the extremely elderly.

Authors:  L M Brunt; M A Quasebarth; D L Dunnegan; N J Soper
Journal:  Surg Endosc       Date:  2001-05-02       Impact factor: 4.584

Review 4.  Gallstone disease: Epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intrahepatic).

Authors:  Susumu Tazuma
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

5.  Laparoscopic cholecystectomy in octogenarians.

Authors:  D Hazzan; N Geron; D Golijanin; P Reissman; E Shiloni
Journal:  Surg Endosc       Date:  2003-03-06       Impact factor: 4.584

6.  Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial.

Authors:  Djemila Boerma; Erik A J Rauws; Yolande C A Keulemans; Ignace M C Janssen; Clemens J M Bolwerk; Ron Timmer; Egge J Boerma; Huug Obertop; Kees Huibregtse; Dirk J Gouma
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

Review 7.  Pathogenesis of gallstones.

Authors:  M C Carey
Journal:  Am J Surg       Date:  1993-04       Impact factor: 2.565

8.  Long-term consequence of endoscopic sphincterotomy for bile duct stones.

Authors:  M Tanaka; S Takahata; H Konomi; H Matsunaga; K Yokohata; T Takeda; N Utsunomiya; S Ikeda
Journal:  Gastrointest Endosc       Date:  1998-11       Impact factor: 9.427

9.  Does cholecystectomy after endoscopic sphincterotomy prevent the recurrence of biliary complications?

Authors:  K H Lai; L F Lin; G H Lo; J S Cheng; R L Huang; C K Lin; J S Huang; P I Hsu; N J Peng; L P Ger
Journal:  Gastrointest Endosc       Date:  1999-04       Impact factor: 9.427

10.  Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis.

Authors:  F Prat; N A Malak; G Pelletier; C Buffet; J Fritsch; A D Choury; C Altman; C Liguory; J P Etienne
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

View more
  5 in total

1.  Effects of cholecystectomy on recurrent biliary complications after endoscopic treatment of common bile duct stone: a population-based cohort study.

Authors:  Chi-Tung Cheng; Chun-Nan Yeh; Kun-Chun Chiang; Ta-Sen Yeh; Kuan-Fu Chen; Shao-Wei Chen
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

2.  Prophylactic cholecystectomy offers best outcomes following ERCP clearance of common bile duct stones: a meta-analysis.

Authors:  Gearóid Mc Geehan; Conor Melly; Niall O' Connor; Gary Bass; Shahin Mohseni; Magda Bucholc; Alison Johnston; Michael Sugrue
Journal:  Eur J Trauma Emerg Surg       Date:  2022-09-02       Impact factor: 2.374

3.  A nationwide population-based study of common bile duct stone recurrence after endoscopic stone removal in Korea.

Authors:  Byung Kyu Park; Jeong Hun Seo; Han Ho Jeon; Jong Won Choi; Sun Young Won; Yong Suk Cho; Chun Kyon Lee; Haeyong Park; Dong Wook Kim
Journal:  J Gastroenterol       Date:  2017-11-30       Impact factor: 7.527

4.  Cholecystectomy outcomes after endoscopic sphincterotomy in patients with choledocholithiasis: a meta-analysis.

Authors:  Jie Xu; Chuang Yang
Journal:  BMC Gastroenterol       Date:  2020-07-17       Impact factor: 3.067

5.  Cholecystectomy for Prevention of Recurrence after Endoscopic Clearance of Bile Duct Stones in Korea.

Authors:  Myung Eun Song; Moon Jae Chung; Dong Jun Lee; Tak Geun Oh; Jeong Youp Park; Seungmin Bang; Seung Woo Park; Si Young Song; Jae Bock Chung
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.